Unmet Need for Thromboembolic Disease

Change what's possible for thrombotic disease graphic

Cardiovascular and thromboembolic diseases are among the leading causes of death and disability, accounting for nearly 1 million deaths in the US annually. ^1,2

THROMBOSIS IS A COMMON MANIFESTATION ACROSS DIFFERENT DISEASE STATES¹:

Thromboembolism due to atrial fibrillation (AFib)
Venous thromboembolism
Cancer-associated thrombosis
Ischemic heart disease
Cerebrovascular disease, including stroke

40% of AFib patients are untreated or undertreated graphic

While direct oral anticoagulants (DOACs) are effective at reducing the risk of recurrent thromboembolic events for patients with AFib, potential bleeding risk contributes to gaps in protection, which may leave patients vulnerable to an event.⁴

~25% of strokes are recurrent, many of which are preventable graphic

Patients who have experienced ischemic stroke, or a TIA, are at risk for a recurrent event.⁶

Could a different target change how management of thromboembolic events is approached?

^aAccording to a cohort study of over 80,000 patients with a diagnosis of either AFib or atrial flutter. ^bBased on data from the US indicating approximately 795,000 individuals experience a stroke each year, of which approximately 185,000 are recurrent.⁵

References

Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res. 2016;118(9):1340-1347. doi:10.1161/CIRCRESAHA.115.306841
Martin SS, Aday AW, Allen NB, et al. 2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association. Circulation. 2025;151(8):e41-e660. doi: 10.1161/CIR.0000000000001303
Ullal AJ, Holmes DN, Lytle BL, et al. Achievement and quality measure attainment in patients hospitalized with atrial fibrillation: results from the Get With The Guidelines - Atrial Fibrillation (GWTG-AFIB) registry. Am Heart J. 2022:245:90-99. doi: 10.1016/j.ahj.2021.12.002.
Fredenburgh JC, Weitz JI. Factor XI as a target for new anticoagulants. Hamostaseologie. 2021;41(2):104-110. doi:10.1055/a-1384-3715
Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. Stroke. 2021;52(7):e364-e467. doi:10.1161/STR.0000000000000375
Tsao CW, Aday AW, Almarzooq ZI, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-e621. doi:10.1161/CIR.0000000000001123

Cardiovascular and thromboembolic diseases are among the leading causes of death and disability, accounting for nearly 1 million deaths in the US annually. 1,2

THROMBOSIS IS A COMMON MANIFESTATION ACROSS DIFFERENT DISEASE STATES1:

While direct oral anticoagulants (DOACs) are effective at reducing the risk of recurrent thromboembolic events for patients with AFib, potential bleeding risk contributes to gaps in protection, which may leave patients vulnerable to an event.4

Patients who have experienced ischemic stroke, or a TIA, are at risk for a recurrent event.6

Could a different target change how management of thromboembolic events is approached?

Cardiovascular and thromboembolic diseases are among the leading causes of death and disability, accounting for nearly 1 million deaths in the US annually. ^1,2

THROMBOSIS IS A COMMON MANIFESTATION ACROSS DIFFERENT DISEASE STATES¹:

While direct oral anticoagulants (DOACs) are effective at reducing the risk of recurrent thromboembolic events for patients with AFib, potential bleeding risk contributes to gaps in protection, which may leave patients vulnerable to an event.⁴

Patients who have experienced ischemic stroke, or a TIA, are at risk for a recurrent event.⁶